NEW YORK, Feb. 12, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM), an industry leader in cannabinoid research and commercial hemp product development, is proud to announce that it is launching a hemp-based Oral Care Division.
The Company has filed a provisional patent relating to the unique formulation of its cannabinoid-containing oral care products. These formulations will target the daily use market as well as remedies for use in resolution of oral care infections and gum diseases.
"We are extremely proud to announce Oral Care as one of AXIM's many industry-leading divisions," states George E. Anastassov, MD, DDS, MBA and AXIM's Chief Executive Officer. "At AXIM, we are focusing on research and development of commercial hemp-derived cannabinoids when it comes to oral health."
Dr. Anastassov continues, "We know that certain cannabinoids act as effective anti-inflammatory, bactericidal, anti-proliferative, and regenerating agents. We also know that the oral cavity, being continuously traumatized by chewing, speaking, and being populated with numerous infectious organisms, is in need of oral health products. For these reasons, we are very proud and extremely excited to announce that AXIM is creating a new category within the oral care consumer products market."
AXIM will pioneer new patent-pending formulations for products in these categories:
- Oral rinse liquid
Through unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. CBD, CBG, CBN, among others), AXIM is focused upon finding solutions for conditions for which there is currently no effective treatment. The Company's initiatives encompass the complete use of the industrial hemp plant leaving a net negative carbon footprint on the environment.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 858-380-5478.
AXIM Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
CONTACT: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Source:AXIM Biotechnologies, Inc